Sökning: onr:"swepub:oai:DiVA.org:liu-51402" >
Early abciximab adm...
Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1-year mortality in patients with high-risk profile. Results from EUROTRANSFER Registry
-
- Rakowski, Tomasz (författare)
- Jagiellonian University
-
- Siudak, Zbigniew (författare)
- Jagiellonian University
-
- Dziewierz, Artur (författare)
- Jagiellonian University
-
visa fler...
-
- Birkemeyer, Ralf (författare)
- Schwarzwald Baar Klinikum Villingen Schwenningen
-
- Legutko, Jacek (författare)
- Jagiellonian University
-
- Mielecki, Waldemar (författare)
- Jagiellonian University
-
- Depukat, Rafal (författare)
- Jagiellonian University
-
- Janzon, Magnus (författare)
- Östergötlands Läns Landsting,Linköpings universitet,Kardiologi,Hälsouniversitetet,Kardiologiska kliniken
-
- Stefaniak, Justyna (författare)
- Krakow Cardiovasc Research Institute
-
- Zmudka, Krzysztof (författare)
- Jagiellonian University
-
- Dubiel, Jacek S (författare)
- Jagiellonian University
-
- Partyka, Lukasz (författare)
- Krakow Cardiovasc Research Institute
-
- Dudek, Dariusz (författare)
- Jagiellonian University
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2009
- 2009
- Engelska.
-
Ingår i: AMERICAN HEART JOURNAL. - : Elsevier BV. - 0002-8703. ; 158:4, s. 569-575
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background There are conflicting data on the clinical benefit from early administration of abciximab from a large randomized trial and a registry. However, both sources suggest that a benefit may depend on the baseline risk profile of the patients. We evaluated the role of early abciximab administration in patients with ST-segment-elevation myocardial infarction (STEMI) referred for primary percutaneous coronary intervention stratified by the STEMI Thrombolysis In Myocardial Infarction (TIMI) risk score. Methods A total of 1,650 patients were enrolled into the EUROTRANSFER Registry. One thousand eighty-six patients received abciximab (66%). Abciximab was administered early in 727 patients (EA) and late in 359 patients (LA). We used the TIMI risk score for risk stratification. Patients with scores 3 constituted the high-risk group of 616 patients (56.7%), whereas 470 patients formed the low-risk cohort. Factoring in the timing of the abciximab administration resulted in 4 groups of patients who were compared for mortality at 1 year: EA/high-risk (n = 413); LA/high-risk (n = 203); EA/low-risk (n = 3 14); LA/low-risk (n = 156). Baseline difference was accounted for by means of propensity score. Results In high-risk patients, 1-year mortality was significantly lower with early abcximab compared to late administration (8.7% vs 15.8%; odds ratio 0.51, CI 0.31-0.85, P = .01). In multivariable Cox regression analysis, both early abciximab administration and patients risk profile (TIMI score :3) were identified as independent predictors of 1-year mortality. Conclusions Early abciximab administration before transfer for percutaneous coronary intervention in STEMI shows lower mortality at 1-year follow-up. This effect is confined to patients with higher risk profile as defined by TIMI risk score andgt;= 3.
Nyckelord
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Rakowski, Tomasz
-
Siudak, Zbigniew
-
Dziewierz, Artur
-
Birkemeyer, Ralf
-
Legutko, Jacek
-
Mielecki, Waldem ...
-
visa fler...
-
Depukat, Rafal
-
Janzon, Magnus
-
Stefaniak, Justy ...
-
Zmudka, Krzyszto ...
-
Dubiel, Jacek S
-
Partyka, Lukasz
-
Dudek, Dariusz
-
visa färre...
- Artiklar i publikationen
-
AMERICAN HEART J ...
- Av lärosätet
-
Linköpings universitet